Ciclesonide noninferiority to placebo on growth velocity

Pediatrics

Volumn 122, Issue 3, 2008, Pages 676-677

  Kassai, Behrouz ^a,b,c   Cucherat, Michel ^a   Bellon, Gabriel ^a,b,c  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c HOSPICES CIVILS DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CICLESONIDE; ANTIALLERGIC AGENT; PREGNANE DERIVATIVE;

CHILD GROWTH; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; GROWTH RATE; HUMAN; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; ASTHMA; CHILD; CHILD DEVELOPMENT; FOLLOW UP; NOTE; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME;

ANTI-ALLERGIC AGENTS; ASTHMA; CHILD; CHILD DEVELOPMENT; FOLLOW-UP STUDIES; HUMANS; PREGNENEDIONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 51649129119     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-0578     Document Type: Letter

References (3)

1. Skoner DP, Maspero J, Banerji D; Ciclesonide Pediatric Growth Study Group. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics. 2008; 121(1). Available at: www.pediatrics.org/cgi/content/full/121/ 1/e1
2. Le Henanff A, Giraudeau B, Baron G, Ravaud P. Quality of reporting of noninferiority and equivalence randomized trials. JAMA. 2006;295(10):1147-1151
3. Garattini S, Bertele V. Non-inferiority trials are unethical because they disregard patients' interests. Lancet. 2007;370(9602):1875-1877